Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy. - Wikidata - wikimedia - TriplyDB

Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy.

Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy.

http://www.wikidata.org/entity/Q41197789

about

Eccentric exercise facilitates mesenchymal stem cell appearance in skeletal muscle The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophy Stem cells for skeletal muscle regeneration: therapeutic potential and roadblocks Laminin regulates PDGFRβ(+) cell stemness and muscle development.Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy Laminin therapy for the promotion of muscle regeneration Gait disturbances in dystrophic hamsters.Substrate and strain alter the muscle-derived mesenchymal stem cell secretome to promote myogenesis.Laminin-111 improves skeletal muscle stem cell quantity and function following eccentric exercise Transgenic expression of Laminin α1 chain does not prevent muscle disease in the mdx mouse model for Duchenne muscular dystrophy.Slowing down differentiation of engrafted human myoblasts into immunodeficient mice correlates with increased proliferation and migration.Laminin-α1 LG4-5 domain binding to dystroglycan mediates muscle cell survival, growth, and the AP-1 and NF-κB transcription factors but also has adverse effects.Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy Membrane-stabilizing copolymers confer marked protection to dystrophic skeletal muscle in vivo.Laminin-211 in skeletal muscle function.Advancing biomaterials of human origin for tissue engineering.Understanding the Role of ECM Protein Composition and Geometric Micropatterning for Engineering Human Skeletal Muscle Cell-matrix interactions in muscle disease.Neuromuscular electrical stimulation promotes development in mice of mature human muscle from immortalized human myoblasts.Laminin 521 maintains differentiation potential of mouse and human satellite cell-derived myoblasts during long-term culture expansion.Laminin: loss-of-function studies.Influence of exercise and aging on extracellular matrix composition in the skeletal muscle stem cell niche.Increased Expression of Laminin Subunit Alpha 1 Chain by dCas9-VP160.Laminin differentially regulates the stemness of type I and type II pericytes.Low molecular weight dextran sulfate binds to human myoblasts and improves their survival after transplantation in mice.Treating pediatric neuromuscular disorders: The future is now.

P2860

Q21560888-FCC7233D-1D88-4F5D-B208-2DAC67463AA2 Q26827638-F2DF510E-C855-4A39-8A1E-0A72089E4B40 Q26828390-792F758D-5133-4121-B17F-735897ACF8AA Q27318580-BED30BDD-5B4E-4E17-878F-177E4C219215 Q28082625-8388662F-D03B-40AC-B41A-323C4076EBA8 Q28087548-B0B0B33C-3AA8-457C-81CE-A82AC252EF04 Q30498131-4CBEF7A5-73E9-49E7-9C15-391E8D5BC4EB Q33900539-B6F380E9-1BC4-4DB3-9D3F-300271B7BC14 Q34109413-B6919841-FDFA-4335-8E0A-B1C589867722 Q34805388-0DB86335-6B8C-4F2D-B365-EBB9F5EB36F1 Q35665198-06C7D04E-596B-408B-9B73-2B667E3BFE5C Q35849199-E6F8F88B-1BDD-4CB6-AED4-F7B0711B02F8 Q35952091-F7209859-4FE9-47D4-ACE8-67C57FB2DF4C Q36270889-C94D532B-996F-40D0-9B0E-799045B0B6A6 Q36531788-E5BEC395-9820-42B5-93AD-9346AF6D539C Q36729634-4DEBEFDB-BD8A-4748-AA03-DB38023EFFEE Q36936313-E81CD611-0233-4DE4-800A-EC7F9E26354E Q37944530-FD118C12-1860-4889-85F1-34B7B9F5A925 Q38658555-E4E92AFC-4769-440F-AD44-B96A708E2AD1 Q38783290-87635DE0-426C-4EC5-8D21-49EBC928A0CC Q38815433-C5729018-7EDF-4122-97BA-CD794427EFFB Q38931350-968B3AC7-F44C-46ED-BA18-F860A25FD5E4 Q42091026-1FCBE57E-735B-41C1-B090-5A74729A05E1 Q42323278-69598A6E-442D-4CE4-AE44-57CCE789BF42 Q43419500-44658AA2-2B6C-4BEE-B32F-1F65B0963F7D Q52756417-61057C1E-9DED-4D06-A188-33AEEE1178F1

P2860

Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy.

http://www.wikidata.org/entity/Q41197789

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy.

@en

type

label

Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy.

@en

prefLabel

Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy.

@en

P1433

Q41197789-4A8A79E5-FCA0-47DE-970A-39B7ACBF971F

P1476

Q41197789-DDA01E21-FB97-4DA7-9CB1-2846CCE03A48

P2093

Q41197789-365DE347-5B16-4A01-A90F-9DC24D3DF152

Q41197789-4760E39A-9AE4-4187-AC11-6E39593DA477

Q41197789-8FFF1A7F-B73D-49AC-B13B-AD4F49ADACAA

Q41197789-931D9034-18A0-4009-B5FC-8A9CC9ACDF05

Q41197789-98773B44-A1D6-4327-A21A-BC06BE7C953A

Q41197789-A6199833-6446-4C52-9213-49BA90D5EDFC

Q41197789-D58D1C4D-F9FD-47A7-95C8-31BC574A0ED2

P2860

Q41197789-09EF25CB-37B4-476B-AD55-E2A4EAABACE5

Q41197789-14C9DEDF-A756-424E-A0DF-7A356A1906B0

Q41197789-22DAC5F9-0A65-49C5-AF86-F54ECFE4FDA6

Q41197789-240BC865-58FE-49B0-A32A-398FAF2312AD

Q41197789-2F50DE72-0DE2-44CA-8335-030A62E633E7

Q41197789-2F8CD72B-43F2-41FF-8869-AD0782B64C98

Q41197789-354A8752-C40F-45C5-B68B-CE691C9D8586

Q41197789-371F2467-68F1-40A3-85A5-B9D84908E9AA

Q41197789-3B6CEC99-522A-4B8F-85F6-AE99CA66359B

Q41197789-40E985DB-05EF-4355-BAAC-624F08EF0E67

P304

Q41197789-1C0D67DD-8932-4095-910B-F1D47462A247

P31

Q41197789-5853354B-47A9-4897-A765-32F26A3A7E7E

P356

Q41197789-7C8682E5-F718-49D5-8C3A-E93E5E099C80

P433

Q41197789-9D25A80D-417D-448B-9DED-90E7EE8B003B

P478

Q41197789-EDFF2FE4-34DF-413E-B861-7539B0F1F9E0

P50

Q41197789-216CB2ED-8C69-4A3A-84AC-D82E53E757D2

P577

Q41197789-0810FC41-01F8-467E-92F4-1F7ABE414E12

P5875

Q41197789-B41E023A-1B7E-4E81-926D-D93D5C892BA7

P698

Q41197789-E0BCDE12-A90B-4E79-87EC-62BE65770559

P932

Q41197789-23D663D3-171D-466A-95B1-A814CF38A2DF

P356

P1433

Molecular Therapy

P1476

Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy.

@en

P2093

Daniel Skuk

http://www.w3.org/2001/XMLSchema#string

Jacques P Tremblay

http://www.w3.org/2001/XMLSchema#string

Joël Rousseau

http://www.w3.org/2001/XMLSchema#string

Jérôme Frenette

http://www.w3.org/2001/XMLSchema#string

Nicolas Dumont

http://www.w3.org/2001/XMLSchema#string

Sébastien Goudenege

http://www.w3.org/2001/XMLSchema#string

Yann Lamarre

http://www.w3.org/2001/XMLSchema#string

P2860

Laminin-1-induced migration of multiple myeloma cells involves the high-affinity 67 kD laminin receptor

A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice

Integrin alpha6beta1-laminin interactions regulate early myotome formation in the mouse embryo

New functions for the matrix metalloproteinases in cancer progression

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

Matrix metalloproteinases: a review

Measurement tools used in the study of eccentric contraction-induced injury.

The alpha7beta1 integrin in muscle development and disease.

Progress in myoblast transplantation: a potential treatment of dystrophies.

Intramuscular transplantation of human postnatal myoblasts generates functional donor-derived satellite cells.

P304

2155-2163

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2010.165

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Jérôme Frenette

P577

2010-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45494781

http://www.w3.org/2001/XMLSchema#string

P698

20683444

http://www.w3.org/2001/XMLSchema#string

P932

2997583

http://www.w3.org/2001/XMLSchema#string